% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

  • kevinmik kevinmik Dec 22, 2010 9:33 AM Flag

    Amylin's Revenue Potential...

    Byetta BID Type II = $300 million - $ 500 million
    Byetta BID + Basal Insulin Type I = $$500 - $1 billion
    Bydureon Injection = $1 billion - $2 billion
    Bydureon Pen = $1 billion - $4 billion
    Symlin Type I = $100 million - $300 million
    Pramlintide + Leptin Obesity = $500 million - $3 billion
    Pramlintide + Leptin + Pyy-3 = $500 million - $5 billion
    Metreleptin Type I = ?
    Metreleptin Lipodystrophy = ?
    Exenatide Monthly = ?
    Exenatide Patch = ?
    Biocon = ?
    Psylin = ?
    Amylin's Peptide Library = ?
    Amylin's Manufacturing Plant = ?

    Bydureon Pen would just add additional value above those seen with injection and adding Pyy-3 to Pram + Lep also just adds additional value above Pram + Lep alone.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Byetta BID Type II = $300 million - $ 500 million
      Byetta BID + Basal Insulin Type I = $$500 - $1 billion???
      where did you get such a number??????
      Bydureon Injection = $1 billion - $2 billion- This was before the 20 month delay and now the competitiors will eat into that when Amylin finally gets approval
      Bydureon Pen = $1 billion - $4 billion - ???where did you get this one?
      Symlin Type I = $100 million - $300 million

      Symlin is a failure peaking out at 80 M in sales and relegated to the co drug in obesity. The Byetta insulin therapy replaces symlin

      Pramlintide + Leptin Obesity = $500 million - $3 billion -- not even starting Phase3 - it is an injection.

      Amylin's Manufacturing Plant = ? I think Takeda will love to convert a lot of this plant

      Just guesses also - )

      • 1 Reply to terry_amln
      • Hi Terry,

        I respect your opinion and agree, we are all just guessing. I'll be the first to admit, I was wrong in the past when it came to projecting Symlin's and Byetta's revenue potential. Symlin has delievered no where near the revenue number I expected it would do and Byetta has been a disspointment. That being said, I still believe in the revolutionary science behind Amylin's Diabetes and Obesity franchises and I expect their huge game changing capabilities will eventually be realized. My first 10 years in Amylin have been sucessful going from an weighted average stock price of $4 starting in 1999 to $15 today, which is actually much better than what the overall market has delivered over the same period. That's not exactly what I was hoping for, but I expect to see my original investment growth objective to play out over the next 5 to 10 years, that is unless the company is sold.


    • Thank God for Yahoo's ignore option.. it keeps me from having to waste my time reading foolish messages. You know who you are and if I had an ability to totally ban you from appearing on my screen including your ID, I would !!!!!

      Have a nice holiday and new year.....

      • 1 Reply to kevinmik
      • THAT is the fundamental problem. You just can't comprehend that it is NOT YOUR SCREEN. You think that this MB is your own private podium. You think you can blather jibberish all day long and waste bandwidth with your idiotic and unendingly repetitious nonsense on YOUR SCREEN. LOL!!! You think that your utter NONSENSE should not be challenged on YOUR FRIGGIN' SCREEN. Not only are you unbelievably stupid and delusional you are an arrogant PR*&%K. Seeing what is supposed to be a public discussion forum filled EVERY SINGLE DAY with your drooling banality is a shame. Why don't you STFU and let some discussion sprout in the wasteland you have created. (I can answer that - because you are an obsessive compulsive jerk off and have nothing else except a failed "investment" in your pathetic life) GFY

    • Stop smoking crack and GET A JOB!